Abbvie Inc

NYSE: ABBV
$189.45
-$0.23 (-0.1%)
Closing Price on October 29, 2024

ABBV Articles

The November 30 short interest data have been compared with the previous figures, and short interest decreased in these selected pharmaceutical stocks.
With money expected to come out of the bond market, these four stocks are an attractive alternative that have solid upside potential, and they are the highest conviction picks at Jefferies.
The November 15 short interest data have been compared with the previous figures, and short interest was mixed in the selected pharmaceutical stocks.
With earnings for the third quarter over, and the fourth quarter of 2016 in full swing, many of the top companies we follow on Wall Street are making some changes to the lists of their high...
Drug prices have been under pressure due to the campaign rhetoric, and short interest has increased in most of these selected pharmaceutical stocks.
In a recent research note, the analysts at Jefferies make a big move by removing a top medical devices company from the firm's well-respected Franchise Picks list of stocks.
The relentless populist rhetoric has lowered the prices on some of the top pharmaceutical companies, and long-term growth and income investors have a chance to buy some great stocks on sale.
The top analyst upgrades, downgrades and initiations seen on Monday morning include AbbVie, Chevron, Home Depot, Nike, Qualcomm and VMware.
AbbVie reported mixed third-quarter financial results and a dividend hike before the markets opened on Friday.
Four companies in four very different sectors that all offer liquidity, a degree of safety and solid dividends that should continue to rise.
The October 14 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
Earnings season is now in full swing, and we have put together a preview of Bristol-Myers, AbbVie and some of the other top players in the health care sector.
A new Jefferies research report features top pharmaceutical picks for the fourth quarter. Any of these top picks make good sense for long-term growth and income portfolios.
The September 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest was mixed.
In a new research report from Jefferies, many of the outstanding companies in pharmaceuticals and biotech space show up among the stocks to buy.